Brookstone Capital Management lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 12.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,850 shares of the medical instruments supplier's stock after purchasing an additional 1,907 shares during the quarter. Brookstone Capital Management's holdings in Becton, Dickinson and Company were worth $4,089,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in BDX. Timber Creek Capital Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $3,691,000. IFM Investors Pty Ltd boosted its position in shares of Becton, Dickinson and Company by 9.0% during the 1st quarter. IFM Investors Pty Ltd now owns 57,878 shares of the medical instruments supplier's stock worth $13,954,000 after acquiring an additional 4,792 shares in the last quarter. 44 Wealth Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $414,000. Calamos Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 1.1% during the 1st quarter. Calamos Advisors LLC now owns 61,868 shares of the medical instruments supplier's stock worth $14,171,000 after acquiring an additional 688 shares in the last quarter. Finally, Palisade Capital Management LP boosted its position in shares of Becton, Dickinson and Company by 15.0% during the 1st quarter. Palisade Capital Management LP now owns 49,900 shares of the medical instruments supplier's stock worth $11,430,000 after acquiring an additional 6,522 shares in the last quarter. 86.97% of the stock is owned by institutional investors.
Insiders Place Their Bets
In related news, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by company insiders.
Becton, Dickinson and Company Trading Up 1.0%
Shares of NYSE:BDX traded up $1.65 during mid-day trading on Tuesday, reaching $174.60. 1,908,132 shares of the company's stock were exchanged, compared to its average volume of 2,069,887. The firm has a market capitalization of $50.04 billion, a price-to-earnings ratio of 33.32, a PEG ratio of 1.31 and a beta of 0.25. The business's fifty day moving average price is $173.29 and its 200-day moving average price is $207.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. Becton, Dickinson and Company's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.17 earnings per share. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 9th were paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 79.39%.
Analysts Set New Price Targets
BDX has been the topic of several analyst reports. Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $260.00 to $185.00 in a research report on Friday, May 2nd. Stifel Nicolaus reduced their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Morgan Stanley cut their target price on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their target price for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Bank of America lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a research report on Thursday, May 1st. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of "Hold" and an average price target of $219.22.
Check Out Our Latest Stock Analysis on BDX
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
